NVO
Novo Nordisk A/S
Every pitch and position made on this ticker, across every competition and newsletter issue in the archive.
- Times pitched
- 2
- Long / short
- 2 / 0
- Avg. return
- —
- Verdicts
- Worked 1 Inconclusive 1
position
Fall 2024
Pine Stone Asset Management
long
worked
Newsletter
Novo Nordisk has disrupted the diabetes treatment market with its GLP-1 drugs, which have created a larger market opportunity despite impacting its own insulin business. The company has consistently g
position
Fall 2024
long
inconclusive
Newsletter
Nadim Rizk mentioned owning shares in Novo Nordisk, highlighting its strong fundamentals and growth prospects in the pharmaceutical sector, particularly in diabetes care.